SCHEMBL292045

SCHEMBL292045

[CH2]Cc1ccsn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6245620 0.70
SCHEMBL9216583 0.69
SCHEMBL10726868 0.66
SCHEMBL11627946 0.66
SCHEMBL22534262 0.66
SCHEMBL6852037 0.64
SCHEMBL21311233 0.64 TLR8 (0.31)
SCHEMBL22534261 0.61
SCHEMBL1067525 0.58
SCHEMBL292468 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100577658-C Quinazoline derivatives ASTRAZENECA AB 2010-01-06 CN claimed
EP-2091929-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS The European Molecular Biology Laboratory (DE) 2009-08-26 EP claimed
CN-101421257-A Agents that disrupt cellular replication and their use in inhibiting pathological conditions EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) 2009-04-29 CN claimed
WO-2007107352-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2007-09-27 WO claimed
JP-2007506716-A 2007-03-22 JP claimed
US-20070043010-A1 Quinazoline derivatives ASTRAZENECA UK LIMITED (GB) 2007-02-22 US claimed
CN-1886399-A Quinazoline derivatives ASTRAZENECA AB (SE) 2006-12-27 CN claimed
EP-1670786-A1 QUINAZOLINE DERIVATIVES Astrazeneca AB (SE) 2006-06-21 EP claimed
WO-2005030757-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-04-07 WO claimed
US-11890296-B2 Anti-tumor agent containing cytarabine, anti- tumor effect enhancing agent which is used in combination with cytarabine, anti-tumor kit, and anti-tumor agent which is used in combination with cytarabine FUJIFILM CORPORATION (JP) 2024-02-06 US disclosed
CN-106458904-B N-substituted sulfonamide compound and process for producing the same 宇部兴产株式会社 2021-12-03 CN disclosed
EP-3858361-A1 ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE FUJIFILM Corporation (JP) 2021-08-04 EP disclosed
EP-3156396-B1 METHOD FOR PRODUCING A N-SUBSTITUTED SULFONAMIDE COMPOUND UBE INDUSTRIES (JP) 2021-07-21 EP disclosed
US-20210213040-A1 ANTI-TUMOR AGENT CONTAINING CYTARABINE, ANTI-TUMOR EFFECT ENHANCING AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE, ANTI-TUMOR KIT, AND ANTI-TUMOR AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE FUJIFILM CORPORATION (JP) 2021-07-15 US disclosed
EP-0170192-A1 Penicillin derivatives as anti-inflammatory and antidegenerative agents MERCK & CO. INC. (US) 1986-02-05 EP disclosed
US-4547371-A Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents MERCK & CO., INC. (US) 1985-10-15 US disclosed
US-4472309-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-09-18 US disclosed
US-4304718-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-08 US disclosed
US-4264498-A REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-04-28 US disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US disclosed